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Abstract
Background A short period of leg immobilization leads to
rapid loss of muscle mass and strength. Creatine supple-
mentation has been shown to increase lean body mass in
active individuals and can be used to augment gains in
muscle mass and strength during prolonged resistance-type
exercise training.
Objective Our objective was to investigate whether cre-
atine loading can attenuate the loss of muscle mass and
strength during short-term leg immobilization.
Methods Healthy young men (n = 30; aged 23 ± 1 years;
body mass index [BMI] 23.3 ± 0.5 kg/m-2) were ran-
domly assigned to either a creatine or a placebo group.
Subjects received placebo or creatine supplements (20 g/d)
for 5 days before one leg was immobilized by means of a
full-leg cast for 7 days. Muscle biopsies were taken before
creatine loading, prior to and immediately after leg
immobilization, and after 7 days of subsequent recovery.
Quadriceps cross-sectional area (CSA) (computed tomog-
raphy [CT] scan) and leg muscle strength (one-repetition
maximum [1-RM] knee extension) were assessed before
and immediately after immobilization and after 1 week of
recovery. Data were analyzed using repeated measures
analysis of variance (ANOVA). Data are presented con-
sistently as mean ± standard error of the mean (SEM).
Results There was a significant overall increase in muscle
total creatine content following the 5-day loading phase
(p = 0.049), which appeared driven by an increase in the
creatine group (from 90 ± 9 to 107 ± 4 mmol/kg-1 dry
muscle) with no apparent change in the placebo group
(from 88 ± 4 to 90 ± 3 mmol/kg-1; p = 0.066 for
time 9 treatment interaction). Quadriceps muscle CSA
had declined by 465 ± 59 and 425 ± 69 mm2 (p\ 0.01)
in the creatine and placebo group, respectively, with no
differences between groups (p = 0.76). Leg muscle
strength decreased from 56 ± 4 to 53 ± 4 kg in the cre-
atine and from 59 ± 3 to 53 ± 3 kg in the placebo group,
with no differences between groups (p = 0.20). Muscle
fiber size did not change significantly over time in either
group (p[ 0.05). When non-responders to creatine loading
were excluded (n = 6), responders (n = 8; total creatine
content increasing from 70 to 106 mmol/kg-1) showed
similar findings, with no signs of preservation of muscle
mass or strength during immobilization. During the sub-
sequent recovery phase, no differences in muscle mass or
strength were found between the two groups (p[ 0.05).
Conclusion Creatine supplementation prior to and during
leg immobilization does not prevent or attenuate the loss of
muscle mass or strength during short-term muscle disuse.
NIH Clinical Trial Registration Number: NCT01894737
(http://www.clinicaltrials.gov/).
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Leg immobilization for 7 days led to a 5.5%
reduction in leg muscle mass and a 7.6% decline in
muscle strength.
Creatine supplementation prior to and during leg
immobilization did not attenuate the decline in leg
muscle mass or strength.
Creatine supplementation did not prevent disuse
atrophy.
1 Background
Recovery from injury or illness often requires a period of
inactivity. Even short periods of disuse lead to a substantial
loss of skeletal muscle mass and strength [1, 2]. The loss of
muscle mass and strength is associated with a longer
recovery period and with a higher risk of injury reoccur-
rence [3, 4]. Moreover, periods of disuse result in reduced
insulin sensitivity [5, 6], a decline in basal metabolic rate
[7], and an increase in body fat mass [8]. These factors
impair physical functioning and decline metabolic health,
causing even more health concerns. Therefore, strategies
are warranted to prevent the loss of muscle mass and/or
strength during short periods of disuse due to injury or
hospitalization.
During the 1990s, creatine supplements became a pop-
ular ergogenic aid for athletes. Creatine monohydrate sup-
plementation can increase the phosphocreatine/creatine
ratio in skeletal muscle tissue, thereby increasing the
capacity for rapid adenosine triphosphate (ATP) resynthesis
during repeated high-intensity exercise tasks [9–11]. In
accordance, creatine supplementation was shown to effec-
tively augment athletic performance during various exercise
tasks characterized by repeated high-intensity exercise and
has since become common practice among many athletes
[12–14]. Besides increasing high-intensity exercise perfor-
mance, creatine supplementation has also been reported to
increase muscle mass and strength in the presence as well as
in the absence of prolonged resistance-type exercise train-
ing [9, 15, 16]. The increase in lean mass following creatine
supplementation has, at least partly, been attributed to water
retention in muscle tissue [11, 17]. The greater osmotic
pressure following the increase in creatine content has been
suggested to result in muscle cell swelling, which is con-
sidered a key stimulus for cell growth [11, 18].
Consequently, it has been hypothesized that creatine
loading prior to immobilization may help to prevent muscle
loss during a short period of disuse [19]. So far, only two
studies have assessed the clinical benefits of creatine sup-
plementation during immobilization to prevent or attenuate
disuse atrophy [20, 21]. Whereas creatine supplementation
attenuated muscle loss during a 1-week arm immobilization
[20], no effect was observed during a 2-week leg immobi-
lization period [21]. Since neither study included a creatine-
loading phase to allow an increase inmuscle creatine content
before immobilization [20, 21], it remains to be determined
whether creatine loading prior to (leg) immobilization can
preserve muscle mass and strength in males.
We hypothesized that creatine loading would prevent or
attenuate the loss of muscle mass and strength during
1 week of leg immobilization. To test our hypothesis, we
selected 30 young males to participate in a study in which
they were subjected to 7 days of single-leg immobilization.
Subjects received either placebo or creatine supplements
from 5 days prior to immobilization until the end of the
study. To assess the effect of creatine loading, muscle
biopsies were taken at baseline and after 5 days of creatine
loading (20 g/d). Before and after 7 days of immobilization
as well as after 7 days of subsequent recovery, we assessed
muscle mass and strength. In addition, muscle biopsies
were taken to assess muscle fiber characteristics.
2 Methods
2.1 Subjects
After screening, 30 healthy young men (aged 23 ± 1 year;
body mass index [BMI] 23.3 ± 0.5 kg/m-2) were included
in the study. Exclusion criteria included a (family) history
of thrombosis; any back, leg, knee, or shoulder complaints
that could interfere with the use of crutches; and any co-
morbidities interacting with mobility or muscle metabolism
of the lower limbs (e.g., arthritis, spasticity/rigidity, all
neurological disorders and paralysis). None of the subjects
reported having performed progressive resistance-type
exercise training or having used creatine supplements,
anticoagulants, corticosteroids, growth hormones, testos-
terone, immunosuppressants, or exogenous insulin over the
previous 6 months. During the screening, subjects gave
written informed consent after they were fully informed
about the nature and possible risks of the experimental
procedures. The study was approved by the Medical Ethics
Committee of the Maastricht University Medical Centre
and performed in accordance with the Declaration of
Helsinki.
2.2 Experimental Design
The study was a double-blind placebo-controlled inter-
vention trial with 30 subjects randomly allocated to receive
E. M. P. Backx et al.
123
either placebo (n = 15) or the creatine supplementation
(n = 15) (Fig. 1). All subjects reported to the laboratory
following an overnight fast on four occasions. Standardized
meals (2.9 MJ, providing 51 energy percent [En %] as
carbohydrate, 32 En % as fat, and 17 En % as protein) were
consumed the evening before all 4 test days. On the first
test visit (baseline), body weight was assessed and a muscle
biopsy sample was taken from the vastus lateralis muscle.
Subjects started with the creatine or placebo supplements
directly after the baseline test. Subjects came back in
5 days after the baseline test for the pre-immobilization
test. During the pre-immobilization test, a second muscle
biopsy was taken to assess the effect of creatine loading on
muscle creatine content and a baseline assessment of
muscle mass (computed tomography [CT] scan upper legs)
was conducted. Muscle strength was estimated using a one-
repetition maximum (1-RM) knee extension test 1 h after
the biopsy; 2 days after the pre-immobilization test, one
leg was immobilized by means of a full leg cast for 7
subsequent days. On the day of the cast removal, and after
7 days of recovery, another muscle biopsy was taken and
muscle mass and strength assessments were repeated.
2.3 Measurements
Body weight was measured with a digital balance with an
accuracy of 0.1 kg (SECA GmbH, Hamburg, Germany).
Muscle biopsies were taken from the middle region of the
vastus lateralis muscle under local anaesthesia, *15 cm
above the patella and *3 cm below entry through the
fascia, using the percutaneous needle biopsy technique
[22]. All biopsies were taken from the leg that was
subsequently immobilized. Muscle samples were dissected
carefully, freed from any visible non-muscle material, and
immediately frozen in liquid nitrogen (biochemical analy-
ses) or liquid nitrogen-cooled isopentane (histochemical
analyses). Muscle samples were stored at –80 C until
further analysis.
Muscle mass was assessed with a single-slice CT scan
(Philips Brilliance 64, Philips Medical Systems, Best, the
Netherlands) to assess the cross-sectional area (CSA) of the
quadriceps muscle. The scanning characteristics were as
follows: 120 kV, 300 mA, rotation time 0.75 s, and field of
view 500 mm. With subjects lying supine with their legs
extended and feet secured, a 3-mm axial image was taken
15 cm proximal to the top of the patella. The precise scan
position was marked with semi-permanent ink for the
duration of the intervention period to ensure accurate
repeated measurements. For analysis, muscle area of the
legs was selected between –29 and 150 Hounsfield units
[23], after which the quadriceps muscle was selected by
manual tracing using ImageJ software (version 1.49p,
National Institute of Health, Maryland, USA) [24–26]. To
estimate muscle strength, 1-RM measurements were per-
formed [5] for each leg individually on a knee extension
machine (Technogym, Rotterdam, The Netherlands). In
short, during the screening visit, the lifting technique was
demonstrated, and a familiarization trial was performed to
ensure proper execution of the exercise protocol. Using the
multiple-repetitions testing procedure [28], 1-RM was
estimated as described previously [27]. This estimate was
then used during the following visits to determine the ini-
tial load for the actual 1-RM test. During the actual 1-RM
test, subjects warmed up and then performed a single
Fig. 1 Schematic overview of the study design. 1-RM one-repetition maximum, CT computed tomography
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repetition with the load set at *90% of the estimated
1-RM. Load was then increased by 2.5–5.0% after each
successful lift, until failure.
2.4 Supplements
The placebo group received a placebo supplement con-
sisting of maltodextrin 7.5 g and dextrose monohydrate
7.5 g (both from AVEBE, Veendam, the Netherlands).
The creatine group received the same supplement with
the addition of creatine monohydrate 5 g (Creapure
AlzChem, Trostberg, Germany). The creatine supple-
ments could not be distinguished from the placebo sup-
plement with respect to color, taste, smell, or appearance.
All subjects were instructed to dissolve the supplement in
lukewarm tap water prior to ingestion. During the first
5 days of creatine loading, subjects consumed four sup-
plements per day (providing a total of creatine 20 g/day
for the creatine group) at breakfast, lunch, dinner, and
immediately before going to bed (approximately 5-h
intervals between supplements). Thereafter, subjects
continued with one supplement per day as a maintenance
dose (containing creatine 5 g per day for the creatine
group) during the subsequent immobilization and recov-
ery period. The applied creatine supplementation protocol
was designed according to the guidelines on creatine
supplementation set by the American College of Sports
Medicine [29].
2.5 Limb Immobilization
At 2 days after the pre-immobilization test, subjects
attended the Casting Room at Maastricht University
Medical Centre at 8.00 a.m. to have a full leg cast fitted
to induce knee immobilization. The leg to be immobilized
was randomized and counter-balanced between left and
right. The circular leg cast extended from 10 cm above
the ankle to approximately 25 cm above the patella. The
knee was casted at a 30 angle of flexion to prevent
subjects from being able to perform any weight-bearing
activities on the casted limb. Subjects were provided with
crutches for proper ambulation. Throughout the immobi-
lization period, subjects were instructed to perform a
series of simple daily ankle exercises (i.e., plantar and
dorsal flexion, and circular movements of the entire foot)
to keep the calf muscle pump activated in the immobi-
lized leg, thereby minimizing the risk of developing deep
vein thrombosis. Prior to the start of the third test visit,
subjects visited the casting room to have the cast
removed. Following cast removal, subjects were trans-
ported by wheelchair to prevent any weight bearing on
the immobilized leg until the muscle biopsy sample was
collected.
2.6 Diet and Physical Activity
Subjects were asked to maintain habitual dietary intake
during the entire intervention period. To check for any
deviations, the participants completed dietary intake
records, including food sources, estimation of the portion
size using household measures, and the timing of intake.
Dietary intake records were completed before and during
the immobilization period on 2 weekdays and 1 weekend
day. DieetInzicht software [7], based on the Dutch food
composition table (NEVO table) 2011, was used to analyze
dietary intake records. Alcohol intake was allowed until
48 h before every test visit. Subjects refrained from any
heavy physical exercise during the entire intervention
period. Therefore, a 3-day activity journal was completed
by the participants on the same days as the dietary intake
records.
2.7 Muscle Total Creatine Analysis
One fraction of the muscle sample (*50 mg wet tissue)
was freeze dried and pulverized. The method of muscle
creatine and creatine phosphate analyses was based upon
the method described by Harris et al. [30]. After adding
perchloric acid (250 ll PCA 1 M for 10 mg dry muscle),
samples were agitated on ice for at least 10 min, after
which they were centrifuged (1000g, 10 min, 4 C).
KHCO3 (105 ll, 2 M) was added to 175 ll of acid extract
to neutralize the samples. Neutralized samples were cen-
trifuged (1000g, 10 min, 4 C), and supernatants were
immediately used for analysis by enzymatic NADH-linked
assay to detect changes in NADH concentration by spec-
trophotometry (Cobas Fara, Roche, Switzerland) at 340 nm
in duplicate. Creatine and phosphocreatine standards (0.8,
1.6, and 3.2 mM) were analyzed in each run of 24 samples.
Muscle total creatine contents were corrected for the
highest ATP value of the same subject to account for
variations in sample impurities (both raw and corrected
data are presented in Table 2).
2.8 Histochemical Analysis
Part of each muscle biopsy sample was frozen in liquid
nitrogen-cooled isopentane. These samples were cut into
5-lm thick cryosections using a cryostat at –20 C. Muscle
biopsies were stained for muscle fiber typing and used to
assess muscle fiber type composition and type I and II
muscle fiber size as described in detail previously [31]. In
short, slides were incubated with primary antibodies
directed against myosin heavy chain (MHC)-I (A4.840,
dilution 1:25; Developmental Studies Hybridoma Bank,
Iowa City, IA, USA) and laminin (polyclonal rabbit antil-
aminin, dilution 1:50; Sigma, Zwijndrecht, the
E. M. P. Backx et al.
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Netherlands). Goat anti-mouse immunoglobulin M (IgM)
AlexaFluor555 and goat anti-rabbit immunoglobulin G
(IgG) AlexaFluor647 were applied as secondary antibodies
(dilution 1:500 and 1:400; Molecular Probes, Invitrogen,
Breda, the Netherlands). Images were captured with a
fluorescent microscope and analyzed for muscle CSA and
fiber-type distribution using ImageJ software.
2.9 Statistics
All data are expressed as means ± standard error of the
mean (SEM). The sample size was based upon a power
calculation with an expected difference in the loss of
quadriceps CSA of 40% between the placebo and creatine
group (respectively, 5 vs. 3% loss of quadriceps CSA) [32].
With a power of 80% and a significance level (a) of 0.05, at
least 13 participants are required per group. To allow for
drop-outs, 30 subjects were included.
An independent t test was used to assess differences in
baseline characteristics between subjects in the placebo and
creatine groups. Our main objective focused on the dif-
ferences between the placebo and the creatine group during
immobilization. We used a two-way repeated measures
analysis of variance (ANOVA) with time (pre-immobi-
lization vs. post-immobilization) as the within-subjects
factor and treatment (creatine and placebo group) as
between-subjects factors to compare changes in quadriceps
CSA, muscle strength, and muscle fiber characteristics
during immobilization. Thereafter, a two-way repeated
measures ANOVA was conducted with time (post-immo-
bilization vs. post-recovery) as within-subjects factor to
test the differences between the placebo and the creatine
groups during the recovery week. A third repeated-mea-
sures ANOVA with all three time points (pre-immobi-
lization, post-immobilization, and post-recovery) was
conducted to test whether the placebo and creatine group
responded differently throughout the whole study period.
For muscle fiber characteristics, a second within-subjects
factor was added (type I vs. II fibers).
The effects of the creatine-loading phase on muscle free
creatine, phosphocreatine, and total creatine, as well as
body weight, were tested using a two-way repeated mea-
sures ANOVA with time (all time points; and baseline vs.
pre-immobilization separately) as within-subjects factor
and treatment (creatine and placebo group) as between-
subjects factors.
In case of a significant time 9 treatment interaction,
paired t tests were performed in the creatine and placebo
groups separately, with Bonferroni correction when
appropriate (i.e., more than two time points). Data were
analyzed using SPSS version 21 (SPSS, IBM Corp.,
Armonk, NY, USA). Results were considered statistically
significant where p B 0.05.
3 Results
3.1 Subjects
Baseline characteristics did not differ between the placebo
and creatine groups (quadriceps CSA 7712 ± 324 and
8194 ± 263 mm2; p = 0.26; and leg muscle strength
56 ± 4 and 59 ± 3 kg; p = 0.47, respectively) (Table 1).
Three subjects withdrew prior to immobilization due to
time constraints. Of the 30 participants, 27 completed the
study (placebo: n = 13; creatine: n = 14).
3.2 Creatine Loading
Muscle tissue free creatine, phosphocreatine, and total
creatine content are displayed in Table 2. At baseline,
muscle total creatine content averaged 89 ± 5 mmol/kg of
dry muscle-1 (mmol/kg-1), with no differences between
the placebo and creatine groups (88 ± 4 vs. 90 ± 9 mmol/
kg-1, respectively; p = 0.68). Despite similar baseline
values, an overall treatment effect was observed when all
time points were included in the analysis, showing that
muscle creatine content was greater in the creatine than in
the placebo group (p = 0.026). When focusing on the
loading phase, a significant main effect of time (p = 0.049)
was observed, showing an overall increase in total creatine
content. Although the time 9 group interaction did not
reach statistical significance (p = 0.066), this increase in
muscle total creatine content appeared to be driven by an
increase in the creatine group (from 90 ± 9 to
107 ± 4 mmol/kg-1 following 5 days of loading), with no
apparent changes in muscle total creatine contents in the
placebo group (from 88 ± 4 to 90 ± 3 mmol/kg-1). In
accordance, a significant time 9 treatment interaction was
observed for muscle free creatine content (p = 0.011), with
post hoc analyses showing a significant increase in the
creatine group (p\ 0.001) with no changes over time in





Age (years) 23 ± 1 23 ± 1
Body weight (kg) 73 ± 3 75 ± 2
Height (m) 1.76 ± 0.03 1.81 ± 0.02
BMI (kg/m-2) 23.5 ± 0.9 23.0 ± 0.5
1-RM (kg) 55 ± 4 59 ± 3
Quadriceps CSA (mm2) 7712 ± 324 8194 ± 263
Data are expressed as the mean ± standard error of the mean. No
differences were found between groups (p[ 0.05)
1-RM one-repetition maximum, BMI body mass index (kgm-2), CSA
cross-sectional area
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the placebo group (Table 2). Correction of the raw data for
ATP contents resulted in higher muscle total creatine
content at baseline (103 ± 3 vs. 108 ± 5 mmol/kg-1 in
the placebo vs. creatine group; p = 0.33), but the pattern of
changes over time was in agreement with the raw data
(Table 2). An overall effect of treatment was observed,
with greater creatine contents in the creatine than in the
placebo group (Table 2; p = 0.032). A main time effect
was shown for the loading phase (p = 0.004), with no
significant time 9 treatment interaction (p = 0.185).
In the creatine group (n = 14), six subjects did not show
an increase in muscle total creatine content exceeding
10 mmol/kg-1 and could therefore be considered non-re-
sponders to creatine loading [10]. In agreement with pre-
vious findings [10, 33], most of these non-responders
showed higher baseline muscle creatine contents than did
the responders (121 ± 8 vs. 70 ± 9 mmol/kg-1;
p\ 0.01). The individual responses to creatine loading are
presented in Fig. 2. In the responders to creatine loading,
we observed a significant increase in total creatine content
in muscle from 70 ± 9 to 106 ± 6 mmol/kg-1 (p\ 0.01).
When correcting these raw data for ATP contents, a sig-
nificant increase was observed from 102 ± 5 to
119 ± 6 mmol/kg-1 (p\ 0.01).
During the loading phase, body weight increased more
in the creatine than in the placebo group (time 9 treatment
interaction p = 0.02). Body weight increased from
73.7 ± 2.2 to 74.4 ± 2.3 kg in the creatine group
(p = 0.01); no changes were observed in the placebo group
(71.2 ± 2.8 to 71.4 ± 2.8 kg; p = 0.39). Within the cre-
atine group, greater increases in body weight were
observed in the responders to creatine loading than in the
non-responders (p = 0.03). Individual changes in body
weight in the responders and non-responders in the creatine
group are presented in Fig. 3.
3.3 Muscle Mass
Leg immobilization resulted in a significant decline in
muscle CSA of the quadriceps muscle (p\ 0.01), with no
differences between groups (Fig. 4; time 9 treatment
interaction p = 0.76). Quadriceps CSA decreased by
5.5 ± 0.8% (from 7712 ± 324 to 7287 ± 305 mm2) in the
placebo group. In the creatine group, quadriceps CSA
decreased by 5.6 ± 0.8% (from 8194 ± 263 to
7729 ± 245 mm2). During the subsequent recovery phase,
Table 2 Muscle creatine content










Free Cr 40 ± 2 44 ± 4 48 ± 4 40 ± 3 34 ± 1 48 ± 4a 53 ± 3a 52 ± 3a
CrP 48 ± 4 45 ± 4 40 ± 4 55 ± 5 55 ± 10 59 ± 6 45 ± 5 52 ± 5
Total Cr 88 ± 4 90 ± 3 87 ± 3 95 ± 4 90 ± 9b 107 ± 4b 98 ± 6b 104 ± 4b
Corrected total
Crc
103 ± 3 107 ± 4 104 ± 4 109 ± 3 108 ± 5b 119 ± 4b 128 ± 6b 124 ± 8b
Data are expressed as mean ± standard error of the mean. Free creatine, creatine phosphate, and total creatine content are expressed in mmol/kg
of dry muscle-1
ANOVA analysis of variance, Cr creatine, CrP creatine phosphate
a Independent t tests showed no differences between treatments at baseline. Repeated measures ANOVA (time 9 treatment) showed significant
time 9 treatment interaction (p = 0.01) for free creatine; Bonferroni corrected post hoc showed a significant increase compared with baseline in
the creatine group only (all p B 0.01)
b Independent t tests showed no differences between treatments at baseline. Repeated measures ANOVA (time 9 treatment) showed significant
treatment effect (p = 0.03) for total creatine
c Total creatine contents corrected for the highest adenosine triphosphate content measured on the four time points of each individual
Fig. 2 Individual changes in muscle total creatine at baseline and
after 5 days of creatine loading in the creatine group. Responders to
creatine supplementation (n = 8) were defined as subjects who
showed an increase in muscle total creatine exceeding 10 mmol/kg-1
[10]. Non-responders (n = 6) were defined as subjects who showed
no increase in muscle total creatine content or an increase\10 mmol/
kg-1 creatine [10]
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quadriceps CSA increased by 2.0 ± 0.6 and 1.1 ± 0.7% in
the placebo and creatine group, respectively (p\ 0.01),
with no differences between groups (time 9 treatment
interaction p = 0.52).
In agreement with the changes in quadriceps CSA, the
CSA of the whole thigh muscle decreased during immo-
bilization in both the placebo (3.6 ± 0.7%) and the cre-
atine (3.7 ± 0.6%) groups, with no differences between
groups (p = 0.76). During the recovery week, whole thigh
muscle CSA of the total group increased by 1.2 ± 0.4%
(p\ 0.01), with no differences between groups
(time 9 treatment interaction p = 0.52).
In the non-immobilized leg, quadriceps muscle CSA did
not change differently in the placebo or creatine group
during immobilization (respectively, –8 ± 33 and
41 ± 48 mm2; time 9 treatment interaction p = 0.41) or
subsequent recovery (respectively, ?62 ± 44 and
?94 ± 47 mm2; time 9 treatment interaction p = 0.63).
The responders to creatine loading showed a change in
quadriceps muscle CSA that was similar to that in the non-
responders to creatine loading during immobilization (re-
spectively, –446 ± 88 and –489 ± 79 mm2) or recovery
(respectively, ?85 ± 41 and ?106 ± 122 mm2).
3.4 Knee Extension Strength
1-RM decreased significantly during leg immobilization
(p\ 0.01), with no differences between groups (Fig. 5;
time 9 treatment interaction p = 0.20). 1-RM decreased by
5.6 ± 2.2% (from 56 ± 4 to 53 ± 4 kg) in the placebo
group and by 9.2 ± 3.1% (from 59 ± 3 to 53 ± 3 kg) in the
creatine group. During the subsequent recovery week, 1-RM
did not increase in either group, and no differences were
found between the two groups (time 9 treatment interaction
p = 0.32). The responders and non-responders to creatine
loading showed a similar change in 1-RM during immobi-
lization (respectively, –5 ± 3 and –8 ± 2 kg) and recovery
(respectively, ?1 ± 2 and ?3 ± 1 kg).
Fig. 3 Individual changes in body weight in the responders and non-
responders following 5 days of creatine loading. Body weight
changes are calculated as post-loading minus baseline values
Fig. 4 Changes in cross-sectional area of the quadriceps muscle in
the creatine and placebo group following 7 days of one-legged knee
immobilization and 7 days of subsequent recovery. Data were
analyzed by two-way repeated measures analysis of variance, with
time as a within-subjects factor and treatment (creatine and placebo
group) as between-subjects factors. Data are expressed as mean ± s-
tandard error of the mean. Immobilization resulted in a significant
decline in quadriceps cross-sectional area in both groups (asterisk),
with no differences between groups. Quadriceps cross-sectional area
increased during the recovery week (asterisk), with no differences
between groups. CSA cross-sectional area
Fig. 5 Changes in the one-repetition maximum as an estimate of leg
muscle strength in the creatine and placebo group, following 7 days
of one-legged knee immobilization and 7 days of subsequent
recovery. Data were analyzed by two-way repeated measures
ANOVA with time as a within-subjects factor and treatment (creatine
and placebo group) as between-subjects factors. Data are expressed as
means ± standard error of the mean. Immobilization resulted in a
significant decline in muscle strength in both groups (asterisk), with
no differences between groups. Muscle strength did not change during
the recovery week, with no differences between groups. 1-RM one-
repetition maximum
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1-RM in the non-immobilized leg increased during the
immobilization period by 3.0 ± 1.5% (from 61 ± 2 to
63 ± 2 kg; p = 0.03), with no differences between the
placebo and creatine groups (time 9 treatment interaction
p = 0.90). 1-RM in the non-immobilized leg did not
change during the subsequent recovery week (p = 0.57).
3.5 Muscle Fiber Characteristics
Muscle fiber characteristics are presented in Table 3. At
baseline, type I and II muscle fiber size averaged
6458 ± 334 and 7263 ± 375 lm2, respectively
(p = 0.01), with no differences between groups. No sig-
nificant changes in type I or II muscle fiber size were
observed following leg immobilization or during subse-
quent recovery. The proportion of type I and type II muscle
fibers was 39 ± 3 and 61 ± 3%, respectively, before the
loading period. No changes in muscle fiber type compo-
sition were observed over time or between groups. No
differences were observed in fiber size between responders
and non-responders to creatine loading, and no changes
were observed over time in either group.
3.6 Diet and Physical Activity
Baseline daily energy intake was 8.2 ± 0.4 MJ per day,
with no differences between groups (p = 0.26). Dietary
protein intake averaged 1.1 ± 0.1 g/kg-1 body weight per
day, with no differences between groups (p = 0.61). Nei-
ther daily energy nor protein intake changed significantly
during the subsequent immobilization and recovery period.
4 Discussion
The present study shows that 7 days of one-legged knee
immobilization results in a substantial decrease in muscle
mass and strength in healthy young men. Creatine loading
prior to immobilization and creatine supplementation
during immobilization did not attenuate the loss of muscle
mass or strength during immobilization. In addition, cre-
atine supplementation failed to accelerate muscle mass or
strength regain during 1 week of subsequent recovery.
Short-term disuse leads to substantial losses in muscle
mass and strength. The current study demonstrates that
merely 7 days of disuse leads to 5.5 ± 0.5% loss of muscle
mass (Fig. 4), representing 0.8% loss of muscle mass per
day. This muscle loss is in line with earlier work [1, 32, 34]
and underlines the impact of even short periods of disuse.
Besides the loss of muscle mass, muscle strength, as esti-
mated by 1-RM, declined by 7.6 ± 2.0% (Fig. 5).
Although maximal leg strength measurements may have
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prior to strength testing, we observed declines in muscle
strength (1–2% per day) similar to those reported previ-
ously in our laboratory as well as by others following a
short period of limb immobilization [1, 32, 34]. The loss of
muscle mass and strength during disuse is associated with a
longer recovery period, a higher risk of injury reoccur-
rence, and a decline in metabolic health [3–6]. Hence,
short-term disuse atrophy is of high clinical relevance, and
effective strategies are needed to preserve muscle mass and
strength during short periods of disuse or bed rest due to
injury or hospitalization [35].
We hypothesized that creatine loading prior to disuse,
thereby increasing muscle creatine content, attenuates the
loss of muscle mass and strength. Therefore, the creatine
group consumed 20 g creatine per day during the 5-day
loading phase, which allowed total creatine content in
muscle to increase by 19%. This loading and maintenance
supplementation scheme has previously been shown to
increase muscle free creatine and creatine phosphate
[9, 11] and is in accordance with the guidelines of the
American College of Sports Medicine [29]. In the present
study, eight subjects showed an increase in total creatine
content of[20%. In the creatine supplemented group, six
subjects did not show a substantial increase in muscle
creatine content (Fig. 2). Subjects not showing differences
in muscle creatine content exceeding 10 mmol/kg-1 were
defined as non-responders [10]. It has been well established
that 15–30% of people who take creatine supplements do
not experience increases in muscle total creatine contents
[9, 10, 33]. Such non-responders to creatine supplementa-
tion typically show high(er) baseline muscle creatine con-
tents, potentially preventing further increases in muscle
creatine content [9, 10, 33]. In agreement, our non-re-
sponders showed substantially greater baseline creatine
contents than responders (108 ± 14 vs. 70 ± 9 mmol/
kg-1, respectively; p = 0.04). We also observed an
increase in body weight in the responders to creatine sup-
plementation, ranging from 0.4 to 1.9 kg, which is in line
with findings of previous studies [9, 10, 29]. The increase
in body weight with creatine loading has been found to
result from water retention due to the increased cellular
osmolarity [11, 17] or the increase in fat-free mass
[9, 15, 16]. The fact that the individuals with an increase in
muscle total creatine content also show an increase in body
weight supports that these subjects are responders to cre-
atine supplementation.
Despite the effective creatine loading, the greater mus-
cle creatine content did not result in the preservation of
muscle mass or strength during 7 days of single-leg
immobilization. Findings were similar when only the
responders to creatine supplementation were included in
the analyses. In addition to the changes in muscle quadri-
ceps CSA, we also assessed potential disuse atrophy on a
muscle fiber level in the vastus lateralis muscle. Average
type I and type II muscle fiber CSA showed no net changes
following immobilization in both the placebo and creatine
group (Table 3). The absence of a detectable decline in
muscle fiber size following short-term immobilization has
been reported previously [2] and is attributed to the sub-
stantial inter- and intra-subject variation in muscle fiber
sizes [36]. Of course, the vastus lateralis muscle does not
per se represent the entire quadriceps muscle. Furthermore,
a muscle biopsy sample taken from the mid region of the
vastus lateralis does not necessarily represent the entire
muscle. Therefore, we can only assume that the presented
data extend to all upper and/or lower leg muscles.
Though the current study focused on the impact of
creatine loading on the decline in muscle mass and strength
during immobilization, we also assessed changes in muscle
mass and leg strength during the acute stages of recovery
from disuse. We observed a 1.5 ± 0.5% regain in skeletal
muscle mass after 1 week of recovery. Although signifi-
cant, this increase in muscle mass represents only 26% of
the muscle mass that was lost during the 7-day immobi-
lization period. Thus, to regain all muscle mass after a
period of disuse, the time required for rehabilitation will be
much longer than the duration of the disuse period itself.
Interestingly, no detectable regain in leg strength was
observed after the first week of recovery. Creatine sup-
plementation did not affect muscle mass or leg strength
regain. Hespel et al. [21] previously showed greater muscle
regain following a period of disuse when creatine was
supplemented during a more prolonged period of rehabil-
itation including a 10-week resistance-type exercise train-
ing program. Clearly, although we show that creatine
supplementation does not preserve muscle mass during
disuse or support muscle regain during the acute stages of
recovery from disuse, it may still be of benefit in support of
muscle mass and strength regain during more prolonged
active rehabilitation.
We hypothesized that creatine loading prior to and
during immobilization would prevent or attenuate muscle
loss during a short period of immobilization. The increase
in muscle creatine content following creatine loading cre-
ates an osmotic potential that forces water in the muscle,
causing muscle cells to swell [18]. Increases in cell volume
and the impact on cell volume homeostasis have been
associated with muscle anabolism [18]. Despite the suc-
cessful creatine loading prior to the immobilization period,
the greater muscle creatine content did not prevent or
attenuate the decline in muscle mass or strength that is
typically observed during short-term disuse. Therefore, in
spite of frequent speculation on the clinical advantage of
creatine supplementation during disuse, we have to remove
creatine from the list of potential nutritional or pharma-
ceutical compounds that may help to prevent disuse
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atrophy. Of course, creatine supplementation can still
provide an ergogenic advantage in anaerobic energy pro-
vision required during exhaustive intermittent-type exer-
cise. As such, creatine supplementation may be used during
clinical rehabilitation to augment the skeletal muscle
adaptive response to prolonged resistance-type exercise
training. However, it should be noted that muscle loss
during disuse occurs at a rate that is several-fold greater
than muscle (re)gain during resistance-type exercise train-
ing. Therefore, it is imperative that we continue our
endeavor to identify nutritional or pharmaceutical com-
pounds that may prevent or attenuate disuse atrophy [35].
5 Conclusion
Creatine supplementation prior to and during leg immobi-
lization does not prevent or attenuate the loss of muscle mass
or strength during short-term muscle disuse in males.
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